


Navigating Complexities in Hematology Trial Imaging



Hematology clinical trials are particularly complex, as they often require both imaging and a comprehensive review of clinical data, leading to very quick deliverable timeline expectations. Perceptive's operational strength and scientific knowledge meet the challenge head-on.

We have supported over 370 hematology studies across a wide range of indications including malignant and non-malignant conditions such as sickle cell disease. For hematologic malignancies, we have vast expertise across criteria, including:

► Lugano ► Lyric ► IMWG ► RECIL ► IWCLL ► IPNHLSS ► IWWM ► TMTV

Why choose Perceptive Imaging

Proven ability to deliver on tight timelines with uncompromised data quality

Success story: Delivered 1,200+ radiology and 1,500+ oncology reads for a multiple myeloma trial, achieving critical milestones on aggressive timelines. Breakthrough Therapy Designation granted and now FDA and EMA approved.

Extensive experience in hematology trials with global regulatory approvals

Our team has supported over **370 malignant and non-malignant hematology trials**, contributing to **over 70 regulatory approvals** and **17 Breakthrough Therapy designations**.

Broad KOL network featuring renowned advisors and internal experts


Perceptive's approach connects sponsors to a network of leading KOLs, including Bruce Cheson, MD, Shaji Kumar, MD, and Joseph Mikhael, MD, as well as our internal hematology experts.

Expert protocol consultation

We design our approach to capture all essential imaging and clinical details from the start, supporting analysis, biomarkers, and efficacy endpoints with regulatory confidence.

24/7 support for seamless communication and issue resolution

Close collaboration with sponsors and globally positioned teams keeps trials moving forward, with rapid escalations ensuring efficient and successful outcomes.



Hematology Experience

	TRIALS IN HEMATOLOGY	TOTAL 370+	APPROVALS 70+
MALIGNANT HEMATOLOGY	Non-Hodgkins Lymphoma (NHL)	75+	15+
	Follicular non-Hodgkin's Lymphoma (fNHL)	40+	9
	Diffuse Large B-Cell Lymphoma (DLBCL)	25+	6
	Pediatric NHL	4	-
	Chronic Lymphocytic Leukemia (CLL)	65+	15+
	Multiple Myeloma	45+	10+
	Myelofibrosis	40	8
	Waldenstrom macroglobulinemia	8	7
	Acute myeloid leukemia (AML)	3	-
BENIGN HEMATOLOGY	Sickle cell disease	4	1
	Beta-Thalassemia	2	-
17 HEMATOLOGY BREAKTHROUGH THERAPY APPROVALS SUPPORTED			

Note:
Additional
hematology
indications
supported
beyond those
listed.

Meet Our Hematology Experts

Meet Perceptive's hematology experts, whose deep clinical trial imaging expertise supports every phase of your hematology trial, from protocol design to regulatory success.



Gregory Goldmacher
MD, PhD, MBA
Chief Scientific &
Medical Officer



Manish Sharma, MD
Chief Scientific Officer,
Oncology



Peter Eggleton MD, FFPM
VP, Scientific & Medical
Services



Rohit Sood, MD, PhD
VP, Scientific and Medical
Services



Rushdia Yusuf MD, MPH
Consultant

How can we help?

Let's solve your hematology study challenges. Contact:

▶ hello@perceptive.com